Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Endo eyes the future and shuns shortages

Executive Summary

Endo has no appetite for “going back and redeveloping” injectable drugs that are in short supply, because the firm’s focus remains on higher-value “technically-challenging products” and paragraph IV patent-challenge opportunities, according to the company’s president and chief executive officer, Paul Campanelli.

You may also be interested in...



Endo Slashes Loss Despite Generics Slide

Endo sharply reduced its net loss in the first quarter, beating analysts’ earnings forecasts. While generics sales slid, revenues from its higher-margin sterile injectables unit soared.

Endo Breaks Off Deal To Acquire Somerset And Wintac

Endo has announced that it will not pursue a previously-announced US$190 million deal to augment its injectables portfolio and pipeline by acquiring Somerset Therapeutics and its India-based Wintac contract development and manufacturing business. The news comes as Endo has reported US generics sales down by a third – and total turnover down by 15% – in 2018.

Zydus Walks Away From US Dapagliflozin Appeal, ANDA Discontinued

In a blow to potential US generic competition, Zydus Cadila has withdrawn its appeal to an unfavorable federal ruling involving a US Farxiga (dapagliflozin) patent.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB001454

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel